Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
      • Doodle Gallery
      • Circulation Cover Doodle
        • → Blip the Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
      • Recently Published Guidelines
    • Bridging Disciplines
    • → Articles Bridging Discplines
    • Go Red for Women Issue
    • Cardiovascular Case Series
    • Circulation at ESC
    • Circulation at AHA Scientific Sessions
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation at ACC 2018
    • Circulation Supplements
    • ECG Challenge
    • Hospitals of History
      • Brigham and Women's Hospital
      • Hartford Hospital
      • Hospital Santa Maria del Popolo, Naples, Italy
      • Instituto do Coração-INCOR (São Paulo, Brasil)
      • Minneapolis City Hospital
      • Parkland Hospital: Dallas, Texas
      • Pennsylvania Hospital, Philadelphia
      • Pitié-Salpêtrière Hospital
      • Royal Infirmary of Edinburgh, Scotland
      • Tufts Medical Center
      • University of Michigan
      • Uppsala University Hospital
      • Vassar Brothers Medical Center (Poughkeepsie, NY)
      • Wroclaw Medical University
      • Women's College Hospital, Toronto, Canada
      • Henry Ford Hospital, Detroit, Michigan
      • Instituto Nacional de Cardiología Ignacio Chávez – INCICh México City, México
      • Kuang-Tien General Hospital (Taichug, Taiwan)
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
      • Accepted Manuscripts
      • Revised Manuscripts
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • General Statistics
    • Circulation Doodle
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
    • Subscribe to AHA Journals
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Bridging Disciplines
    • → Articles Bridging Discplines
    • Go Red for Women Issue
    • Cardiovascular Case Series
    • Circulation at ESC
    • Circulation at AHA Scientific Sessions
    • Global Impact of the 2017 ACC/AHA Hypertension Guidelines
    • Circulation at ACC 2018
    • Circulation Supplements
    • ECG Challenge
    • Hospitals of History
    • On My Mind
    • Podcast Archive
    • → Subscribe to Circulation on the Run
    • →Circulation FIT Podcast 2018
    • → #FITFAVs
  • Resources
    • Instructions for Authors
    • → Article Types
    • → General Preparation Instructions
    • → Research Guidelines
    • → How to Submit a Manuscript
    • Journal Policies
    • Permissions and Rights Q&A
    • Submission Sites
    • Circulation CME
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Core 6: Vascular Disease: Catheter-Based and Surgical Interventions

Abstract 4521: AT2 Signaling is a Positive Prognostic and Therapeutic Modifier of Marfan Syndrome: Lessons on the Inequality of ACEi and ARBs

Jennifer P Habashi, Tammy M Holm, Jefferson J Doyle, Hamza Aziz, Djahida Bedja, Hal C Dietz
Circulation. 2009;120:S963
Jennifer P Habashi
Johns Hopkins Univ, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tammy M Holm
Johns Hopkins Univ, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jefferson J Doyle
Johns Hopkins Univ, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hamza Aziz
Johns Hopkins Univ, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Djahida Bedja
Johns Hopkins Univ, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hal C Dietz
Johns Hopkins Univ, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics

Jump to

  • Article
  • Info & Metrics
  • eLetters
Loading

Abstract

Marfan syndrome(MFS), a disorder that includes aortic aneurysm, is caused by mutations in the fibrillin-1 gene(FBN1). Murine models demonstrated that excess TGFβ signaling causes many manifestations of MFS including aortic aneurysm, which can be attenuated by antagonizing TGFβ with neutralizing antibody or the AngII type 1(AT1) receptor blocker losartan. TGFβ can signal through canonical (pSmad2/3) and noncanonical (MAPK, e.g. pERK1/2) cascades and their relative contribution to MFS has not previously been elucidated. We show that both pathways are activated in the ascending aorta in a mouse model of MFS(Fbn1+/−). Signaling of AngII through AT1 increases the expression of TGFβ ligands, receptors and activators, while signaling through AT2 is thought to antagonize these events in some cell types. Induction of AT2 signaling by AT1 blockade may contribute to the protective effect of losartan. AT2 signaling can also induce apoptosis, leading to the proposal that the dual AT1/AT2 blockade via ACEi is preferable. To address this, we disrupted the Agtr2 gene (encoding AT2;AT2KO) in Fbn1+/− mice. AT2KO:Fbn1+/− mice showed larger aortic dimensions by echocardiography than Fbn1+/− mice at 8 weeks (p<0.001), and this difference was maintained until sacrifice at 1 year of age. AT2KO:Fbn1+/− mice had worse aortic wall architecture, increased wall thickness and reduced elastic fiber content compared to Fbn1+/− alone (p<0.001, 0.01 and 0.001), while mice that lacked the AT2 receptor were identical to WT mice. pERK1/2 was further elevated in the AT2KO:Fbn1+/− mice, and the ERK antagonist U0126 reduced aortic growth in Fbn1+/− animals, suggesting that AT2 signaling is protective through inhibition of ERK signaling. Activation of ERK is both TGFβ and AT1 dependent. Losartan abolished ERK activation and prevented aneurysm progression (p<0.000001) while the ACEi enalapril which had no effect on ERK, did not decrease aortic growth (p=0.06). Losartan’s protection was lost in the AT2KO:Fbn1+/− mice (p<0.0001). AT2 signaling protectively modifies MFS and the selective AT1 antagonist losartan results in a superior clinical outcome. These data implicate MAPK and AT2 signaling in the pathogenesis of aortic aneurysm and identify potential therapeutic targets.

Back to top
Previous Article

This Issue

Circulation
November 3, 2009, Volume 120, Issue Suppl 18
  • Table of Contents
Previous Article

Jump to

  • Article
  • Info & Metrics

Article Tools

  • Citation Tools
    Abstract 4521: AT2 Signaling is a Positive Prognostic and Therapeutic Modifier of Marfan Syndrome: Lessons on the Inequality of ACEi and ARBs
    Jennifer P Habashi, Tammy M Holm, Jefferson J Doyle, Hamza Aziz, Djahida Bedja and Hal C Dietz
    Circulation. 2009;120:S963, originally published January 5, 2016

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Abstract 4521: AT2 Signaling is a Positive Prognostic and Therapeutic Modifier of Marfan Syndrome: Lessons on the Inequality of ACEi and ARBs
    (Your Name) has sent you a message from Circulation
    (Your Name) thought you would like to see the Circulation web site.
  • Share on Social Media
    Abstract 4521: AT2 Signaling is a Positive Prognostic and Therapeutic Modifier of Marfan Syndrome: Lessons on the Inequality of ACEi and ARBs
    Jennifer P Habashi, Tammy M Holm, Jefferson J Doyle, Hamza Aziz, Djahida Bedja and Hal C Dietz
    Circulation. 2009;120:S963, originally published January 5, 2016
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Circulation

  • About Circulation
  • Instructions for Authors
  • Circulation CME
  • Statements and Guidelines
  • Meeting Abstracts
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
200 Fifth Avenue, Suite 1020
Waltham, MA 02451
email: circ@circulationjournal.org
 

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured